Viswanadhan Krishnan 4

What Happened
Viswanadhan Krishnan, Chief of Corporate Development & Strategy at Agios Pharmaceuticals (AGIO), had 8,100 restricted stock units (RSUs) convert to common shares on March 5, 2026, and sold 2,959 of those shares in an open-market transaction at $27.80 per share, generating $82,260. The conversion/exercise of the RSUs is reported at $0.00 per share (typical for RSU settlements). The sale was to cover tax withholding related to the RSU vesting.

Key Details

• Transaction date: March 5, 2026. Filing date: March 9, 2026 (filed within the two-business-day window — timely).
• Conversion/exercise: 8,100 RSUs converted to 8,100 shares, recorded at $0.00.
• Open-market sale: 2,959 shares sold at $27.80, proceeds $82,260.
• Footnotes: Sale executed pursuant to durable automatic sale instructions included in the RSU agreement (consistent with a Rule 10b5-1 plan) to cover tax withholding. Each RSU equals one contingent share; the RSUs were granted March 5, 2025 and vest in three equal annual installments beginning March 5, 2026.
• Shares owned after the transaction: not specified in the provided filing summary.

Context
This was a conversion of RSUs with a partial sale to satisfy tax withholding — a routine administrative transaction rather than an outright unsolicited market sale. For RSU-related transactions, the exercise/conversion is often recorded at $0.00 because the units convert to shares without an out‑of‑pocket purchase; the subsequent sale to cover taxes is common and does not necessarily indicate a view on the company’s prospects.